linjc16/ctgov huggingface dataset:
The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth

Study Overview
=================
Brief Summary
-----------------
This study examines youth's motivation for food or social rewards after a brief episode of simulated ostracism. The investigators hypothesize that youth who think about a friend after being ostracized will mediate their decision to resort to food, which is typically evidenced in socially isolated overweight youth.

Official Title
-----------------
The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth

Conditions
-----------------
Social Exclusion, Control

Intervention / Treatment
-----------------
* Behavioral: Ostracism


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: General liking for all study foods Exclusion Criteria: Food allergies Medical or Psychological disorders

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game. | |
| Other: Ostracism<br>Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game. | Behavioral: Ostracism<br>* Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of food consumed after playing a computer game | Participants' food consumption after playing a computer game is measured at the end of the study session | Measured once during this 3-6 month study | 
| The number of points earned for a snack food or social interaction. | Participants' motivation to earn a reward is measured by the number of mouse clicks participants completed to obtain the reward. | Measured once during this 3-6 month study |
Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents

Study Overview
=================
Brief Summary
-----------------
This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the treatment of children and adolescents with depression or depressive state

Official Title
-----------------
SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placeb-controlled Study

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Fluvoxamine maleate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Have a minimum total score of 18 on the JSIGH-D, Weight is within the standard weight ± 2S.D. based on the standard weight for each age in the School Health Statistical Survey Exclusion Criteria Have the following predominant psychiatric diagnosis -Schizophrenia Have previously been treated with fluvoxamine maleate

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: F<br> | Drug: Fluvoxamine maleate<br>* Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica<br>|
| Placebo Comparator: P<br> | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the time of onset of 50% decrease from baseline in the Japanese Version of the Structured Interview Guide for the Hamilton Depression Rating Scale (JSIGH-D) 17-item total score |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Clinical Global Impression(CGI) improvement at Week 8 |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fluvoxamine Maleate, Depression, Children and Adolescents
Development of 'Emma'--a Pediatric IBD Quiz

Study Overview
=================
Brief Summary
-----------------
We would like to collaborate and further develop an ipad-based, interactive quiz game 'Emma'; to identify gaps in knowledge of inflammatory bowel disease in pediatric patients. These gaps can be used to improve patient education.

Official Title
-----------------
Development of an Electronic Pediatric Inflammatory Bowel Disease Quiz

Conditions
-----------------
Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Other: playing the ipad quiz game


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 10-18 years of age Diagnosis of Crohn's disease or ulcerative colitis English-speaking Established patient of participating institution Exclusion criteria Inability to understand and read English at a grade 5-12 year level, as commensurate to their chronological age Research denial by patient or guardian

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: playing the ipad quiz game<br>There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game) | Other: playing the ipad quiz game<br>* Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in patient knowledge of inflammatory bowel disease | The patient will play the ipad quiz game at office visits over time. We will look for improvements in overall knowledge of IBD, as well as subcategories (ex. nutrition, medications, etc.) | baseline to 18 months |
Arabic Translation and Validation of the (Overactive Bladder Symptom Score) OABSS

Study Overview
=================
Brief Summary
-----------------
The English version of the Overactive Bladder Symptom Score (OABSS) questionnaire was translated to Arabic language. The questionnaire was validated by comparing the response to the questionnaire in a patient with Overactive Bladder (OAB) before and after providing treatment with antimuscarinics.

Official Title
-----------------
Validating 7-items Overactive Bladder Symptom Score (OABSS) Through Arabic Linguistic Version

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Other: Arabic version of the Overactive Bladder Symptom Score Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: More than 20 years Had three months history of overactive bladder symptoms (urgency with or without incontinence and associated with frequency and nocturia). Exclusion Criteria: Active urinary tract infection. Predominant symptoms of urinary stress incontinence; Diabetes mellitus; Previous abdominal and pelvic (urological or gynecological gastrointestinal) surgery; Previous neurological disease.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br> | Other: Arabic version of the Overactive Bladder Symptom Score Questionnaire<br>* All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development and validation of Arabic version of the Overactive Bladder Symptom Score (OABSS) questionnaire |  | 3 months |
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Study Overview
=================
Brief Summary
-----------------
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Official Title
-----------------
Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease

Conditions
-----------------
Percutaneous Coronary Intervention, Renal Insufficiency, Chronic, Cardiac Catheterization

Intervention / Treatment
-----------------
* Drug: Dapagliflozin 10 MG [Farxiga]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>18 years Written informed consent Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 [CKD stage G1-G3] Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients Exclusion Criteria: Active malignancy Class I or equivalent indication for treatment with a SGLT2 inhibitor Pregnancy or willing of pregnancy during the follow up period Active urogenital infection Diabetes mellitus type 1 History of diabetic ketoacidosis Cardiogenic shock eGFR < 29 ml/min/1.73m2

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Dapagliflozin 10mg group<br>Dapagliflozin 10 mg once a day for 1 month after the procedure. | Drug: Dapagliflozin 10 MG [Farxiga]<br>* Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.<br>|
| No Intervention: Non-intervention group<br>No intervention. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of contrast induced nephropathy | Serum creatinine (Scr) elevation of >25% or >0.5 mg/dl (44 μmol/l) from baseline within 48 hours | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sodium-Glucose Transporter 2 Inhibitors, Dapaglifozin, Chronic kidney disease
Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy, safety and tolerability of 0.05% topical cyclosporin eye drop to Refresh in moderate to severe dry eye patients. Null hypothesis is: there is no difference between these two groups.

Detailed Description
-----------------
Inclusion criteria: Participants are moderate to severe dry eye patients aged more than 18 years of age Oxford staining scores of more than five. OSDI scores of more than 0.1 Outcome measurements: Main parameter is staining score (corneal + conjunctival) Other parameter is OSDI score, symptom of ocular surface discomfort score, number of daily artificial tear needed, TBUT, Schirmer I score, cytokines level & markers Safety parameters: VA, IOP, cyclosporin level

Official Title
-----------------
Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: 0.05% cyclosporin eye drop


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moderate to severe dry eye Exclusion Criteria: lid anomaly, previous CsA use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>0.05% cyclosporin | Drug: 0.05% cyclosporin eye drop<br>* bid dosage for 4 months<br>|
| Active Comparator: B<br>Refresh | Drug: 0.05% cyclosporin eye drop<br>* bid dosage for 4 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal and conjunctival staining score |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Schirmer 1 score |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry eye
ISM1 Versus EmbrioGen Media for Embryo Culture With Previous Failure Implantation in ART Treatments

Study Overview
=================
Brief Summary
-----------------
Recently, it has been suggested that culture of embryos in EmbryoGen medium can increase the live birth rate in IVF patients with a previous history of pregnancy loss. Couples requiring IVF treatment and with a past experience of implantation failure will be included in the study. Controlled ovarian stimulation protocol will consist of an agonist down regulation and follicular stimulation by recombinant FSH. Fertilization will be achieved by standard IVF or intracytoplasmic sperm injection. Fertilized eggs will be cultured in 6% CO2, 5% O2, 89% N2 atmosphere in microdrops. In the treatment group EmbryoGen culture medium (EG, Origio, Måløv, Denmark) will be adopted throughout the culture period. In the control group, inseminated oocytes will be cultured in standard culture conditions, i.e. IMS1 medium (ISM1, Origio, Måløv, Denmark), maintaining unchanged all other culture conditions. Procedures of embryo transfer, will be carried out on day 2 using EmbryoGen or ISM1 respectively. The endometrial support will be the same in the two groups.

Official Title
-----------------
Prospective Randomized Controlled Trail to Assess the Efficacy of EmbryoGen Culture Medium to Improve Ongoing Pregnancy and Implantation Rates in IVF Treatments of Patients With a Previous History of Implantation Failure

Conditions
-----------------
Infertility, Implantation Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women experiencing at least two (maximum 4) failures of implantation after ART treatments (with elective embryo transfer) Exclusion Criteria: Frozen spermatozoa Frozen oocytes women PCO and PCOS women with previous pregnancy, miscarriage or biochemical pregnancy
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IVF treatment ISM1<br>Embryo culture in ISM1 medium | |
| IVF treatment EG<br>Embryo culture in EmbryoGen medium | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing Pregnancy Rate after 12 weeks of gestation |  | 12 weeks after conception | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing Implantation Rate after 12 weeks of gestation |  | 12 weeks after conception | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, embryo culture, Ongoing pregnancy rate, Ongoing implantation rate, Miscarriage
Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate if there is any different follow-up results by angiography and IVUS between two different drug-eluting stents after implanted simultaneously in same individuals.

Conditions
-----------------
Drug Eluting Stent

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: These patients who received two kinds of drug-eluting stent (Endeavor and Excel) im simultaneously. Exclusion Criteria: Dual anti-platelet therapy less than 12 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endeavor group and Excel group<br>Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Segment and instent restenosis measured by coronary angiography and IVUS. |  | at 12 months after implantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncovered and malposition of stent. |  | at 12 months after implantation. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug-eluting stent, coronary restenosis, coronary thrombosis
Effect of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Expiratory Flow Volume in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the effect of Acu-TENS on forced expiratory volume in one second (FEV1), a test of pulmonary function used to assess airway resistance, during sub-maximal treadmill exercise in healthy subjects.

Official Title
-----------------
Effect of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Expiratory Flow Volume in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Acu-TENS
* Device: Placebo-TENS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With normal health Exclusion Criteria: Suffered from respiratory, cardiovascular, musculoskeletal, neurological or endocrine disorders No allergic to gel

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Acu-TENS<br>Application of Acu-TENS prior to exercise | Device: Acu-TENS<br>* Application of Acu-TENS (with electrical output from the machine)<br>|
| Placebo Comparator: Placebo-TENS<br>Application of Acu-TENS (without electrical output from the machine) prior to exercise | Device: Placebo-TENS<br>* Application of Acu-TENS (without electrical output from the machine)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forced expiratory flow volume in one second (FEV1)and forced vital capacity (FVC) |  | before and immediate after the exercise test | 
| Forced expiratory flow volume in one second (FEV1) and forced vital capacity (FVC) |  | at 15min, 30 min and 45min after the exercise test | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise duration |  | Immediately after the exercise test | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TENS, acupuncture, FEV1, Normal Healthy subjects
Combinations of Pharmacologic Smoking Cessation Treatments

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Official Title
-----------------
Combinations of Pharmacologic Smoking Cessation Treatments

Conditions
-----------------
Smoking

Intervention / Treatment
-----------------
* Drug: Bupropion
* Drug: Mecamylamine
* Drug: Nicotine Patch


Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bupropion|nan|
|Drug: Mecamylamine|nan|
|Drug: Nicotine Patch|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smoking cessation, bupropion, mecamylamine, nicotine